首页> 美国卫生研究院文献>Stem Cells Translational Medicine >A Practical and Efficient Cellular Substrate for the Generation of Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial Progenitor Cells
【2h】

A Practical and Efficient Cellular Substrate for the Generation of Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial Progenitor Cells

机译:一种实用和有效的细胞基质用于从成人中诱导多能干细胞的生成:血液来源的内皮祖细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Induced pluripotent stem cells (iPSCs) have the potential to generate patient-specific tissues for disease modeling and regenerative medicine applications. However, before iPSC technology can progress to the translational phase, several obstacles must be overcome. These include uncertainty regarding the ideal somatic cell type for reprogramming, the low kinetics and efficiency of reprogramming, and karyotype discrepancies between iPSCs and their somatic precursors. Here we describe the use of late-outgrowth endothelial progenitor cells (L-EPCs), which possess several favorable characteristics, as a cellular substrate for the generation of iPSCs. We have developed a protocol that allows the reliable isolation of L-EPCs from peripheral blood mononuclear cell preparations, including frozen samples. As a proof-of-principle for clinical applications we generated EPC-iPSCs from both healthy individuals and patients with heritable and idiopathic forms of pulmonary arterial hypertension. L-EPCs grew clonally; were highly proliferative, passageable, and bankable; and displayed higher reprogramming kinetics and efficiencies compared with dermal fibroblasts. Unlike fibroblasts, the high efficiency of L-EPC reprogramming allowed for the reliable generation of iPSCs in a 96-well format, which is compatible with high-throughput platforms. Array comparative genome hybridization analysis of L-EPCs versus donor-matched circulating monocytes demonstrated that L-EPCs have normal karyotypes compared with their subject's reference genome. In addition, >80% of EPC-iPSC lines tested did not acquire any copy number variations during reprogramming compared with their parent L-EPC line. This work identifies L-EPCs as a practical and efficient cellular substrate for iPSC generation, with the potential to address many of the factors currently limiting the translation of this technology.
机译:诱导多能干细胞(iPSC)可能会产生用于疾病建模和再生医学应用的患者特异性组织。但是,在iPSC技术可以进入翻译阶段之前,必须克服一些障碍。这些因素包括关于用于重编程的理想体细胞类型的不确定性,重编程的低动力学和效率以及iPSC及其体细胞前体之间的核型差异。在这里,我们描述了使用具有几个有利特性的晚生内皮祖细胞(L-EPC)作为生成iPSC的细胞底物。我们已经开发出一种协议,可以从外周血单核细胞制剂(包括冷冻样品)中可靠分离L-EPC。作为临床应用的原则证明,我们从健康个体和具有遗传性和特发性形式的肺动脉高压患者中产生了EPC-iPSC。 L-EPC呈克隆状增长;具有高度扩散性,可传递性和可信赖性;与真皮成纤维细胞相比,具有更高的重编程动力学和效率。与成纤维细胞不同,L-EPC重编程的高效率允许以96孔格式可靠生成iPSC,与高通量平台兼容。 L-EPC与供体匹配的循环单核细胞的阵列比较基因组杂交分析表明,与受试者的参考基因组相比,L-EPC具有正常的核型。另外,与它们的亲本L-EPC系相比,在重新编程期间,测试的> 80%的EPC-iPSC系没有获得任何拷贝数变化。这项工作确定了L-EPC是iPSC产生的一种实用而有效的细胞底物,具有解决当前限制该技术翻译的许多因素的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号